HRT, breast and endometrial cancers: Strategies and intervention options

Piero Sismondi, Nicoletta Biglia, Maurizia Giai, Riccardo Ponzone, Riccardo Roagna, Luca Sgro, Carlo Campagnoli

Research output: Contribution to journalArticlepeer-review


The demand for hormone replacement therapy (HRT) by women who enter the menopause is rapidly increasing in all developed countries. The concern that HRT may enhance morbidity and mortality from malignant diseases still limits the widespread adoption of hormonal treatments. Overall, epidemiological data on cancer incidence and HRT are reassuring, although long-term or inappropriate therapies may slightly increase the risk of developing malignant diseases. Many commercial hormonal compounds are currently available and the safest HRT regimen with regard to cancer risk must be identified. It is equally important that the best strategies for breast and endometrial surveillance in women commencing HRT be outlined, bearing in mind that the diffusion of hormonal therapies may be halted by unnecessary medical interventions. Copyright (C) 1998 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)131-139
Number of pages9
Issue number3
Publication statusPublished - Aug 16 1999


  • Breast cancer
  • Gynecological cancer
  • HRT

ASJC Scopus subject areas

  • Ageing
  • Obstetrics and Gynaecology


Dive into the research topics of 'HRT, breast and endometrial cancers: Strategies and intervention options'. Together they form a unique fingerprint.

Cite this